Navigation Links
Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
Date:7/15/2009

MORRISTOWN, N.J., July 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida ("Watson"), has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its trospium chloride extended-release 60 mg capsules prior to the expiration of a patent owned by Supernus Pharmaceuticals, Inc. Watson's trospium chloride extended-release capsules are the generic version of Allergan Inc.'s Sanctura XR((R))( )product, which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.

Allergan filed suit against Watson on July 13, 2009 in the U.S. District Court for the District of Delaware seeking to prevent Watson from commercializing its products prior to expiration of U.S. patent number 7,410,978. Allergan's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner.

Watson believes it may be first to file an ANDA for generic trospium extended-release capsules. For the twelve-months ended March 31, 2009, Sanctura XR((R)) had total U.S. sales of approximately $42 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation related to patent infringement; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

Sanctura XR((R)) is a registered trademark of Allergan, Inc.

(Logo:http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
2. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
3. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
4. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
5. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
6. Watson to Acquire Arrow Group
7. Watson Files FDA Application for Generic Mucinex(R) D
8. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
9. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
10. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
11. Watson Files FDA Applications for Generic Mucinex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American ... surprising that bariatric surgery has received increased attention in recent years, as an ... it comes to weight loss, most people are familiar with the basic requirements of ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., the ... has been recognized as one of the best small businesses for new dads by ... of nine small businesses providing progressive benefits to new parents on the organization’s ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... scholarships to students studying complementary medicine. Allison Outerbridge is this year’s Life ... award on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... Eye expert s ... seek an eye examination before leaving ...   Moorfields Eye Hospital Dubai, the first overseas branch ... , has identified premature babies as a special concern in the ... vulnerability to retinopathy of prematurity (ROP). ROP is a potentially blinding ...
(Date:5/27/2016)... Israel , May 27, 2016 ... of the Dario™ Diabetes Management Tool, today announced that the ... at the Marcum MicroCap Conference being held June 1-2 in ... Micro Invitational, being held June 7-9 in Los ... Ben-David will discuss recent corporate and operational milestones, including the ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
Breaking Medicine Technology: